[1] Luo Z, Jegga A G, Bezerra J A. Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies[J]. Hepatology , 2018, 67(2): 676-689.
[2] Miethke A G, Saxena V, Shivakumar P, et al. Post-natal paucity of regulatory T cells and control of NK cell activation in experimental biliary atresia[J]. J Hepatology, 2010, 52(5): 718-726.
[3] Zimmer C L, von Seth E, Buggert M, et al. A biliary immune landscape map of primary sclerosing cholangitis reveals a dominant network of neutrophils and tissue-resident T cells[J]. Sci Transl Med, 2021, 13(599): eabb3107.
[4] Lages C S, Simmons J, Maddox A, et al. The dendritic cell-T helper 17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia[J]. Hepatology, 2017, 65(1): 174-188.
[5] Mohajeri S, Bezabeh T, Ijare O B, et al. In vivo 1 H MRS of human gallbladder bile in understanding the pathophysiology of primary sclerosing cholangitis (PSC): immune-mediated disease versus bile acid-induced injury[J]. NMR Biomed, 2019, 32(5): e4065.
[6] Li T, Chiang J Y L. Bile acid signaling in metabolic and inflammatory diseases and drug development[J]. Pharmacol Rev, 2024, 76(6): 1221-1253.
[7] Kudira R, Yang Z F, Osuji I, et al. Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies[J]. J Hepatol, 2025, 83(5): 1128-1141.
[8] Zhou K, Wang J, Xie G, et al. Distinct plasma bile acid profiles of biliary atresia and neonatal hepatitis syndrome[J]. J Proteome Res, 2015, 14(11): 4844-4850.
[9] Gadaleta R M, van Erpecum K J, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J]. Gut, 2011, 60(4): 463-472.
[10] Fuchs C D, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology[J]. Nat Rev Gastroenterol & Hepatol, 2022, 19(7): 432-450.
[11] Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids[J]. J Biol Chem, 2003, 278(11): 9435-9440.
[12] Liang X, Liu K, Jia X, et al. Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription[J]. Acta Pharm Sin B, 2024, 14(8): 3513-3527.
[13] Studer E, Zhou X, Zhao R, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes[J]. Hepatology, 2012, 55(1): 267-276.
[14] Sakaguchi S, Mikami N, Wing J B, et al. Regulatory T cells and human disease[J]. Annu Rev Immunol, 2020, 38: 541-566.
[15] Li K, Zhang X, Yang L, et al. Foxp3 promoter methylation impairs suppressive function of regulatory T cells in biliary atresia[J]. Am J of Physiol Gastrointest Liver Physiol, 2016, 311(6): G989-G997.
[16] Liao C Y, Barrow F, Venkatesan N, et al. Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis[J]. Front Immunol, 2023, 14: 1130184.
[17] Lu C, Thompson C B. Metabolic regulation of epigenetics[J]. Cell Metabolism, 2012, 16(1): 9-17.
[18] Taylor A E, Carey A N, Kudira R, et al. Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis[J]. Hepatology, 2018, 68(5): 1905-1921.
[19] Miethke A G, Zhang W, Simmons J, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice[J]. Hepatology, 2016, 63(2): 512-523.
[20] Luo Z, Shivakumar P, Mourya R, et al. Gene expression signatures associated with survival times of pediatric patients with biliary atresia identify potential therapeutic agents[J]. Gastroenterology, 2019, 157(4): 1138-1152.e14.
[21] Sandborn W J, Vermeive S, Peyrin Binoulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double blind, placebo-controlled, phase 3 studies[J]. Lancet, 2023, 401(10383):1159-1171. |
